{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:00:52Z","timestamp":1793862052048,"version":"4.6.1"},"reference-count":198,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000271","name":"Science and Technology Facilities Council","doi-asserted-by":"publisher","award":["ST\/Y004183\/1"],"award-info":[{"award-number":["ST\/Y004183\/1"]}],"id":[{"id":"10.13039\/501100000271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.drudis.2025.104407","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T20:04:59Z","timestamp":1750277099000},"page":"104407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance"],"prefix":"10.1016","volume":"30","author":[{"given":"Selene K.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Galgadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Zanetti-Domingues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco L.","family":"Gervasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5496-6300","authenticated-orcid":false,"given":"Marisa L.","family":"Martin-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104407_b0005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/BF01907986","article-title":"Precise mapping of the EGF receptor gene on the human chromosome 7p12 using an improved fish technique","volume":"38","author":"Wang","year":"1993","journal-title":"Jpn J Hum Genet"},{"key":"10.1016\/j.drudis.2025.104407_b0010","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0021-9258(19)68224-4","article-title":"A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles","volume":"257","author":"Cohen","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104407_b0015","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/309418a0","article-title":"Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells","volume":"309","author":"Ullrich","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104407_b0020","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0014-4827(02)00097-6","article-title":"The epidermal growth factor system in Caenorhabditis elegans","volume":"284","author":"Moghal","year":"2003","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.drudis.2025.104407_b0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/cancers9020016","article-title":"Epidermal growth factor pathway signaling in Drosophila embryogenesis: tools for understanding cancer","volume":"9","author":"Lusk","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2025.104407_b0030","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a020768","article-title":"The EGFR family: not so prototypical receptor tyrosine kinases","volume":"6","author":"Lemmon","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.drudis.2025.104407_b0035","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/jcp.21635","article-title":"The epidermal growth factor receptor ligands at a glance","volume":"218","author":"Schneider","year":"2009","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.drudis.2025.104407_b0040","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev-biochem-060614-034402","article-title":"A structural perspective on the regulation of the epidermal growth factor receptor","volume":"84","author":"Kovacs","year":"2015","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.drudis.2025.104407_b0045","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104407_b0050","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1152\/physrev.00030.2015","article-title":"Expression and function of the epidermal growth factor receptor in physiology and disease","volume":"96","author":"Chen","year":"2016","journal-title":"Physiol Rev"},{"key":"10.1016\/j.drudis.2025.104407_b0055","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/307521a0","article-title":"Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences","volume":"307","author":"Downward","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104407_b0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/1759-7714.13246","article-title":"Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: clinical significance and limitations","volume":"11","author":"Smolle","year":"2020","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.drudis.2025.104407_b0065","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.drudis.2025.104407_b0070","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.drudis.2025.104407_b0075","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u2018never smokers\u2019 and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104407_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40880-017-0187-6","article-title":"Proportion and clinical features of never-smokers with non-small cell lung cancer","volume":"36","author":"Cho","year":"2017","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.drudis.2025.104407_b0085","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104407_b0090","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.drudis.2025.104407_b0095","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104407_b0100","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3390\/molecules27030819","article-title":"Structural insight and development of EGFR tyrosine kinase inhibitors","volume":"27","author":"Amelia","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2025.104407_b0105","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/cells8040316","article-title":"Structure and dynamics of the EGF receptor as revealed by experiments and simulations and its relevance to non-small cell lung cancer","volume":"8","author":"Martin-Fernandez","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2025.104407_b0110","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.3390\/cancers15102855","article-title":"Novel targets, novel treatments: the changing landscape of non-small cell lung cancer","volume":"15","author":"de Jong","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2025.104407_b0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.29245\/2689-999X\/2019\/2.1148","article-title":"Pulmonary nano-drug delivery systems for lung cancer: current knowledge and prospects","volume":"3","author":"Amararathna","year":"2019","journal-title":"J Lung Health Dis"},{"key":"10.1016\/j.drudis.2025.104407_b0120","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2025.104407_b0125","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3390\/vaccines11091460","article-title":"Epidermal growth factor receptor-targeted neoantigen peptide vaccination for the treatment of non-small cell lung cancer and glioblastoma","volume":"11","author":"Li","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.drudis.2025.104407_b0130","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0092-8674(02)00741-9","article-title":"The conformational plasticity of protein kinases","volume":"109","author":"Huse","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104407_b0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.molcel.2011.03.004","article-title":"Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms","volume":"42","author":"Jura","year":"2011","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2025.104407_b0140","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1158\/0008-5472.CAN-04-1168","article-title":"A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib) relationships among protein conformation, inhibitor off-rate, and receptor activity","volume":"64","author":"Wood","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2025.104407_b0145","doi-asserted-by":"crossref","first-page":"10761","DOI":"10.3390\/ijms140610761","article-title":"Cellular functions regulated by phosphorylation of EGFR on Tyr845","volume":"14","author":"Sato","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104407_b0150","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1021\/bi900755n","article-title":"In vitro enzymatic characterization of near full length EGFR in activated and inhibited states","volume":"48","author":"Qiu","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2025.104407_b0155","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1593\/tlo.12163","article-title":"EGFR tyrosine 845 phosphorylation-dependent proliferation and transformation of breast cancer cells require activation of p38 MAPK","volume":"5","author":"Mueller","year":"2012","journal-title":"Transl Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0160","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1021\/acs.jcim.8b00458","article-title":"Structural insights into characterizing binding sites in epidermal growth factor receptor kinase mutants","volume":"59","author":"Zhao","year":"2019","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2025.104407_b0165","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.65824","article-title":"Structural basis of the effect of activating mutations on the EGF receptor","volume":"10","author":"Galdadas","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2025.104407_b0170","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.1073\/pnas.1220843110","article-title":"Transitions to catalytically inactive conformations in EGFR kinase","volume":"110","author":"Shan","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2025.104407_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104407_b0180","article-title":"EGFR exon 18 mutations in advanced non-small cell lung cancer: a real-world study on diverse treatment patterns and clinical outcomes","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0185","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ccr.2006.12.017","article-title":"Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity","volume":"11","author":"Yun","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2025.104407_b0190","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"Pao","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2025.104407_b0195","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5858\/arpa.2016-0579-CP","article-title":"Worldwide frequency of commonly Detected EGFR mutations","volume":"142","author":"Graham","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.drudis.2025.104407_b0200","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.1158\/1078-0432.CCR-19-0780","article-title":"The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma","volume":"25","author":"Truini","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104407_b0205","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1038\/s41467-022-34398-z","article-title":"Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations","volume":"13","author":"van Alderwerelt van Rosenburgh","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104407_b0210","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2206588119","article-title":"Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer","volume":"119","author":"Brown","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2025.104407_b0215","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cell.2012.02.063","article-title":"Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization","volume":"149","author":"Shan","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104407_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102671","article-title":"The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: diagnosis and future perspectives","volume":"124","author":"Dorta-Su\u00e1rez","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.drudis.2025.104407_b0225","first-page":"301","article-title":"Tackling drug resistance in EGFR exon 20 insertion mutant lung cancer","volume":"14","author":"Pacini","year":"2021","journal-title":"Pharmacogenom Pers Med"},{"key":"10.1016\/j.drudis.2025.104407_b0230","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2025.104407_b0235","article-title":"EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation that displays sensitivity to approved and in-development lung cancer EGFR tyrosine kinase inhibitors","volume":"1","author":"Vasconcelos","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.drudis.2025.104407_b0240","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.3390\/molecules26216677","article-title":"Globally approved EGFR inhibitors: insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism","volume":"26","author":"Abourehab","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2025.104407_b0245","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-03-0564","article-title":"United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets","volume":"10","author":"Cohen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104407_b0250","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104407_b0255","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1158\/1078-0432.CCR-09-0391","article-title":"Combined survival analysis of prospective clinical trials of gefitinib for non\u2013small cell lung cancer with EGFR mutations","volume":"15","author":"Morita","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104407_b0260","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/BJ20121513","article-title":"Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain","volume":"448","author":"Park","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.drudis.2025.104407_b0265","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1634\/theoncologist.2014-0154","article-title":"Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials","volume":"20","author":"Burotto","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.drudis.2025.104407_b0270","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.3390\/curroncol30060405","article-title":"Afatinib for the treatment of NSCLC with uncommon EGFR mutations: a narrative review","volume":"30","author":"Jiang","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0275","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"JCO"},{"key":"10.1016\/j.drudis.2025.104407_b0280","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s40265-018-1028-x","article-title":"Dacomitinib: first global approval","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2025.104407_b0285","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","article-title":"Overview of current systemic management of EGFR-mutant NSCLC","volume":"29","author":"Hsu","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0290","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-06-1570","article-title":"Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors","volume":"12","author":"Balak","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104407_b0295","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104407_b0300","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2025.104407_b0305","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104407_b0310","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamaoncol.2023.5013","article-title":"First-line osimertinib for previously untreated patients with NSCLC and uncommon EGFR mutations: the UNICORN Phase 2 nonrandomized clinical Trial","volume":"10","author":"Okuma","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0315","article-title":"Efficacy and safety of rociletinib versus chemotherapy in patients with EGFR-mutated NSCLC: the results of TIGER-3, a Phase 3 randomized study","volume":"2","author":"Yang","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.drudis.2025.104407_b0320","doi-asserted-by":"crossref","first-page":"53508","DOI":"10.18632\/oncotarget.18588","article-title":"Structural basis of mutant-selectivity and drug-resistance related to CO-1686","volume":"8","author":"Yan","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2025.104407_b0325","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104407_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102605","article-title":"EGFR exon20 insertion mutations in non-small cell lung cancer: clinical implications and recent advances in targeted therapies","volume":"120","author":"Bai","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.drudis.2025.104407_b0335","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","article-title":"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics","volume":"12","author":"Arcila","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2025.104407_b0340","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20\u2013selective kinase inhibitor in non\u2013small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2025.104407_b0345","unstructured":"Takeda. Takeda\u2019s EXKIVITY\u2122 (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC. www.takeda.com\/newsroom\/newsreleases\/2021\/takeda-exkivity-mobocertinib-approved-by-us-fda\/."},{"key":"10.1016\/j.drudis.2025.104407_b0350","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00044-022-02952-5","article-title":"Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations","volume":"31","author":"Wang","year":"2022","journal-title":"Med Chem Res"},{"key":"10.1016\/j.drudis.2025.104407_b0355","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1158\/1541-7786.MCR-19-0419","article-title":"TAS6417\/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations","volume":"17","author":"Udagawa","year":"2019","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.drudis.2025.104407_b0360","doi-asserted-by":"crossref","first-page":"S1003","DOI":"10.1016\/j.annonc.2022.07.1114","article-title":"987P Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: preliminary analysis of WU-KONG6, the first pivotal study","volume":"33","author":"Wang","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0365","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.drudis.2025.104407_b0370","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.1101637","article-title":"Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways","volume":"305","author":"Sordella","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.drudis.2025.104407_b0375","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1038\/ncomms6811","article-title":"Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks","volume":"5","author":"Chakraborty","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104407_b0380","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Addiction to oncogenes\u2013the Achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.drudis.2025.104407_b0385","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.molmed.2004.08.008","article-title":"Mutations and addiction to EGFR: the Achilles \u2018heal\u2019 of lung cancers?","volume":"10","author":"Gazdar","year":"2004","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.drudis.2025.104407_b0390","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.3390\/ijms20174133","article-title":"A cell\u2019s fate: an overview of the molecular biology and genetics of apoptosis","volume":"20","author":"Cavalcante","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104407_b0395","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/cdd.2017.44","article-title":"Caspases and their substrates","volume":"24","author":"Julien","year":"2017","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.drudis.2025.104407_b0400","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/cdd.2017.179","article-title":"MOMP, cell suicide as a BCL-2 family business","volume":"25","author":"Kalkavan","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.drudis.2025.104407_b0405","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008714","article-title":"Mechanisms of action of Bcl-2 family proteins","volume":"5","author":"Shamas-Din","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.drudis.2025.104407_b0410","doi-asserted-by":"crossref","first-page":"11867","DOI":"10.1158\/0008-5472.CAN-07-1961","article-title":"Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion","volume":"67","author":"Deng","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2025.104407_b0415","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008656","article-title":"Caspase functions in cell death and disease","volume":"5","author":"McIlwain","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.drudis.2025.104407_b0420","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejphar.2008.10.024","article-title":"An epidermal growth factor inhibitor, gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells","volume":"600","author":"Chang","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2025.104407_b0425","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1371\/journal.pmed.0040315","article-title":"BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations","volume":"4","author":"Costa","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.drudis.2025.104407_b0430","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1371\/journal.pmed.0040294","article-title":"Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas","volume":"4","author":"Gong","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.drudis.2025.104407_b0435","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1371\/journal.pmed.0040316","article-title":"Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics","volume":"4","author":"Cragg","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.drudis.2025.104407_b0440","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3390\/genes13122183","article-title":"Mechanisms of EGFR-TKI-induced apoptosis and strategies targeting apoptosis in EGFR-mutated non-small cell lung cancer","volume":"13","author":"Nishihara","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.drudis.2025.104407_b0445","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014568","article-title":"BIM deletion polymorphism predicts poor response to EGFR-TKIs in nonsmall cell lung cancer","volume":"98","author":"Su","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.drudis.2025.104407_b0450","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3390\/cells11142201","article-title":"Diverse mechanisms of resistance against osimertinib, a third-generation EGFR-TKI, in lung adenocarcinoma cells with an EGFR-activating mutation","volume":"11","author":"Nishihara","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2025.104407_b0455","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1158\/1078-0432.CCR-17-1574","article-title":"Overcoming acquired resistance to AZD9291, a third-generation EGFR inhibitor, through modulation of MEK\/ERK-dependent Bim and Mcl-1 degradation","volume":"23","author":"Shi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104407_b0460","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.tranon.2019.02.006","article-title":"The third-generation EGFR inhibitor, osimertinib, promotes c-FLIP degradation, enhancing apoptosis including TRAIL-induced apoptosis in NSCLC cells with activating EGFR mutations","volume":"12","author":"Shi","year":"2019","journal-title":"Transl Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0465","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.7150\/thno.54824","article-title":"Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.drudis.2025.104407_b0470","doi-asserted-by":"crossref","first-page":"19503","DOI":"10.1073\/pnas.0905056106","article-title":"Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition","volume":"106","author":"Faber","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2025.104407_b0475","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","article-title":"TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants \u2013 past, present and future","volume":"25","author":"Sedger","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.drudis.2025.104407_b0480","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.3390\/ijms20164021","article-title":"Blockade of EGFR activation promotes TNF-induced lung epithelial cell apoptosis and pulmonary injury","volume":"20","author":"Yamaoka","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104407_b0485","doi-asserted-by":"crossref","first-page":"8872","DOI":"10.1158\/1078-0432.CCR-05-0811","article-title":"Enhancement of sensitivity to tumor necrosis factor \u03b1 in non\u2013small cell lung cancer cells with acquired resistance to gefitinib","volume":"11","author":"Ando","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104407_b0490","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1172\/JCI96148","article-title":"TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer","volume":"128","author":"Gong","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2025.104407_b0495","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/cdd.2017.169","article-title":"How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?","volume":"25","author":"Aubrey","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.drudis.2025.104407_b0500","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature09870","article-title":"FAS and NF-\u03baB signalling modulate dependence of lung cancers on mutant EGFR","volume":"471","author":"Bivona","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104407_b0505","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s43018-020-0048-0","article-title":"EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer","volume":"1","author":"Gong","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.drudis.2025.104407_b0510","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3390\/cancers14030686","article-title":"Fluorescence imaging of epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer","volume":"14","author":"Martin-Fernandez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2025.104407_b0515","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.cell.2013.08.015","article-title":"EGFR-mediated phosphorylation of beclin 1 in autophagy suppression, tumor progression and tumor chemoresistance","volume":"154","author":"Wei","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104407_b0520","first-page":"1","article-title":"Afatinib induces pro-survival autophagy and increases sensitivity to apoptosis in stem-like HNSCC cells","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2025.104407_b0525","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41388-025-03318-y","article-title":"Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1\/glycolysis\/H3K18la positive feedback loop","volume":"44","author":"Zhang","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2025.104407_b0530","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.21037\/tlcr-21-572","article-title":"Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review","volume":"10","author":"Liu","year":"2021","journal-title":"Translat Lung Cancer Res"},{"key":"10.1016\/j.drudis.2025.104407_b0535","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"key":"10.1016\/j.drudis.2025.104407_b0540","article-title":"Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104407_b0545","doi-asserted-by":"crossref","first-page":"354","DOI":"10.21037\/atm-22-4218","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments\u2014a systematic review","volume":"11","author":"Olivares-Hern\u00e1ndez","year":"2023","journal-title":"Ann Translat Med"},{"key":"10.1016\/j.drudis.2025.104407_b0550","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/JTO.0000000000000500","article-title":"Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation","volume":"10","author":"Chen","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0555","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","article-title":"The tumor microenvironment in the response to immune checkpoint blockade therapies","volume":"11","author":"Petitprez","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104407_b0560","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104407_b0565","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","article-title":"Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy","volume":"16","author":"Mikubo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0570","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1038\/s41467-018-05626-2","article-title":"Notch3-dependent \u03b2-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC","volume":"9","author":"Arasada","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104407_b0575","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.1038\/s41388-019-0887-2","article-title":"Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer","volume":"38","author":"Raoof","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2025.104407_b0580","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41467-018-08074-0","article-title":"AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells","volume":"10","author":"Taniguchi","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104407_b0585","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41591-018-0264-7","article-title":"Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer","volume":"25","author":"Shah","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2025.104407_b0590","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1038\/s41467-024-46531-1","article-title":"Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer","volume":"15","author":"Baroja","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104407_b0595","article-title":"Tumor cell spatial organization directs EGFR\/RAS\/RAF pathway primary therapy resistance through YAP signaling","volume":"14","author":"Nakagawa","year":"2025","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2025.104407_b0600","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fcell.2020.00760","article-title":"Epithelial-mesenchymal transition and metabolic switching in cancer: lessons from somatic cell reprogramming","volume":"8","author":"Lai","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.drudis.2025.104407_b0605","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1158\/1078-0432.CCR-17-1577","article-title":"Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM","volume":"24","author":"Song","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104407_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100773","article-title":"Epithelial-mesenchymal transition in cancer: a historical overview","volume":"13","author":"Ribatti","year":"2020","journal-title":"Transl Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0615","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.drudis.2025.104407_b0620","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1172\/JCI73048","article-title":"CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance","volume":"124","author":"Park","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2025.104407_b0625","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","article-title":"Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non\u2013small-cell lung cancer","volume":"28","author":"Jackman","year":"2010","journal-title":"JCO"},{"key":"10.1016\/j.drudis.2025.104407_b0630","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104407_b0635","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3390\/cancers11081141","article-title":"PTEN in lung cancer: dealing with the problem, building on new knowledge and turning the game around","volume":"11","author":"Gkountakos","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104407_b0640","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1158\/2159-8290.CD-12-0103","article-title":"Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors","volume":"2","author":"Ercan","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2025.104407_b0645","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1158\/0008-5472.CAN-21-0556","article-title":"Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third-generation EGFR tyrosine kinase inhibitor, osimertinib","volume":"81","author":"Zhu","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2025.104407_b0650","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/cancers15030612","article-title":"MET amplification as a resistance driver to TKI therapies in lung cancer: clinical challenges and opportunities","volume":"15","author":"Qin","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104407_b0655","doi-asserted-by":"crossref","first-page":"987","DOI":"10.7150\/jca.63410","article-title":"Activation of the Hedgehog pathway mediates resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer","volume":"13","author":"Chen","year":"2022","journal-title":"J Cancer"},{"key":"10.1016\/j.drudis.2025.104407_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100260","article-title":"Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations","volume":"6","author":"Riudavets","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.drudis.2025.104407_b0665","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/1759-7714.12613","article-title":"ALK-rearrangement in non-small-cell lung cancer (NSCLC)","volume":"9","author":"Du","year":"2018","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.drudis.2025.104407_b0670","article-title":"RET fusion testing in patients with NSCLC: the RETING study","volume":"5","author":"Conde","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.drudis.2025.104407_b0675","article-title":"Successful treatment and retreatment with erdafitinib for a patient with FGFR3-TACC3 fusion squamous NSCLC: a case report","volume":"4","author":"Pham","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.drudis.2025.104407_b0680","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0685","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","article-title":"Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin","volume":"16","author":"Oser","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0690","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: from basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.drudis.2025.104407_b0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113959","article-title":"The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC","volume":"156","author":"Li","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2025.104407_b0700","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1120278","article-title":"Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC","volume":"13","author":"Peng","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0705","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib alone versus gefitinib plus chemotherapy for non\u2013small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study","volume":"38","author":"Hosomi","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.drudis.2025.104407_b0710","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2009-0317","article-title":"Bevacizumab","volume":"15","author":"Kazazi-Hyseni","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.drudis.2025.104407_b0715","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1238579","article-title":"Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis","volume":"14","author":"Zheng","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2025.104407_b0720","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0725","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.2014.60.7317","article-title":"Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non\u2013small-cell lung cancer","volume":"33","author":"Scagliotti","year":"2015","journal-title":"JCO"},{"key":"10.1016\/j.drudis.2025.104407_b0730","first-page":"1","article-title":"RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer","volume":"20","author":"Wang","year":"2022","journal-title":"J Transl Med"},{"key":"10.1016\/j.drudis.2025.104407_b0735","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non\u2013small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104407_b0740","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221144930","article-title":"Safety and efficacy of Mek inhibitors in the treatment of plexiform neurofibromas: a retrospective study","volume":"30","author":"Cacchione","year":"2023","journal-title":"Cancer Control"},{"key":"10.1016\/j.drudis.2025.104407_b0745","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104407_b0750","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14737140.2021.1919090","article-title":"Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence","volume":"21","author":"Santoni","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.drudis.2025.104407_b0755","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1002\/mco2.342","article-title":"Targeting drug-tolerant cells: a promising strategy for overcoming acquired drug resistance in cancer cells","volume":"4","author":"Song","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.drudis.2025.104407_b0760","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nchembio.2085","article-title":"An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells","volume":"12","author":"Vinogradova","year":"2016","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2025.104407_b0765","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature24297","article-title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104407_b0770","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","article-title":"Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway","volume":"37","author":"Kurppa","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2025.104407_b0775","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.celrep.2015.03.012","article-title":"NF-\u03baB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer","volume":"11","author":"Blakely","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2025.104407_b0780","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.616546","article-title":"An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer","volume":"12","author":"Qi","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0785","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.cell.2006.05.013","article-title":"An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor","volume":"125","author":"Zhang","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104407_b0790","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/376313a0","article-title":"Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex","volume":"376","author":"Jeffrey","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104407_b0795","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0092-8674(02)00963-7","article-title":"Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains","volume":"110","author":"Ogiso","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104407_b0800","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0092-8674(02)00940-6","article-title":"Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha","volume":"110","author":"Garrett","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104407_b0805","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cell.2012.12.032","article-title":"Conformational coupling across the plasma membrane in activation of the EGF receptor","volume":"152","author":"Endres","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104407_b0810","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cell.2009.04.025","article-title":"Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment","volume":"137","author":"Jura","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104407_b0815","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.molcel.2009.04.034","article-title":"The juxtamembrane region of the EGF receptor functions as an activation domain","volume":"34","author":"Red Brewer","year":"2009","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2025.104407_b0820","doi-asserted-by":"crossref","first-page":"13307","DOI":"10.1038\/ncomms13307","article-title":"EGFR oligomerization organizes kinase-active dimers into competent signalling platforms","volume":"7","author":"Needham","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104407_b0825","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.14107","article-title":"Molecular basis for multimerization in the activation of the epidermal growth factor receptor","volume":"5","author":"Huang","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2025.104407_b0830","doi-asserted-by":"crossref","first-page":"30392","DOI":"10.1074\/jbc.M504770200","article-title":"Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-a multidimensional microscopy analysis","volume":"280","author":"Clayton","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104407_b0835","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1617994114","article-title":"EGF and NRG induce phosphorylation of HER3\/ERBB3 by EGFR using distinct oligomeric mechanisms","author":"van Lengerich","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.drudis.2025.104407_b0840","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1016\/j.celrep.2018.02.031","article-title":"Phosphorylated EGFR dimers are not sufficient to activate Ras","volume":"22","author":"Liang","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2025.104407_b0845","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2025.104407_b0850","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104407_b0855","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/annonc\/mdm474","article-title":"Randomized phase II study of cetuximab plus cisplatin\/vinorelbine compared with cisplatin\/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer","volume":"19","author":"Rosell","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0860","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","article-title":"Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial","volume":"16","author":"Thatcher","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0865","article-title":"The latest battles between EGFR monoclonal antibodies and resistant tumor cells. Front","volume":"10","author":"Cai","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0870","volume":"29","author":"Guo","year":"2021","journal-title":"Amivantamab: a potent novel EGFR\/c-MET bispecific antibody therapy for EGFR-mutated non-small cell lung cancer"},{"key":"10.1016\/j.drudis.2025.104407_b0875","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.annonc.2022.02.031","article-title":"22P EMB-01: an EGFR-cMET bispecific antibody, in advanced\/metastatic solid tumors phase I results","volume":"33","author":"Qing","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0880","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jtho.2018.01.009","article-title":"EGFR T790M and C797S mutations as mechanisms of acquired resistance to dacomitinib","volume":"13","author":"Kobayashi","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0885","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2025.104407_b0890","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104407_b0895","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1158\/1078-0432.CCR-22-3901","article-title":"BBT-176, a novel fourth-generation tyrosine kinase inhibitor for osimertinib-resistant EGFR mutations in non\u2013small cell lung cancer","volume":"29","author":"Lim","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104407_b0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111055","article-title":"Immunotherapy for colorectal cancer: rational strategies and novel therapeutic progress","volume":"126","author":"Rastin","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2025.104407_b0905","doi-asserted-by":"crossref","first-page":"10616","DOI":"10.1073\/pnas.1221953110","article-title":"Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase","volume":"110","author":"Sutto","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.drudis.2025.104407_b0910","doi-asserted-by":"crossref","first-page":"38244","DOI":"10.1074\/jbc.M112.414391","article-title":"Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor","volume":"287","author":"Lu","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104407_b0915","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002179","article-title":"Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases","volume":"7","author":"Dixit","year":"2011","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.drudis.2025.104407_b0920","doi-asserted-by":"crossref","first-page":"E3595","DOI":"10.1073\/pnas.1220050110","article-title":"Mechanism for activation of mutated epidermal growth factor receptors in lung cancer","volume":"110","author":"Red Brewer","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104407_b0925","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1038\/s41467-018-06632-0","article-title":"The architecture of EGFR\u2019s basal complexes reveals autoinhibition mechanisms in dimers and oligomers","volume":"9","author":"Zanetti-Domingues","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104407_b0930","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1038\/s41467-024-46284-x","article-title":"Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers","volume":"15","author":"Iyer","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104407_b0935","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0006-3495(02)75585-9","article-title":"Preformed oligomeric epidermal growth factor receptors undergo an ectodomain structure change during signaling","volume":"82","author":"Martin-Fernandez","year":"2002","journal-title":"Biophys J"},{"key":"10.1016\/j.drudis.2025.104407_b0940","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/jmi.13151","article-title":"A perspective of fluorescence microscopy for cellular structural biology with EGFR as witness","volume":"291","author":"Martin-Fernandez","year":"2023","journal-title":"J Microsc"},{"key":"10.1016\/j.drudis.2025.104407_b0945","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1042\/BST20130236","article-title":"Structure-function relationships and supramolecular organization of the EGFR (epidermal growth factor receptor) on the cell surface","volume":"42","author":"Needham","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.drudis.2025.104407_b0950","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/onc.2012.21","article-title":"Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor","volume":"32","author":"Yoshikawa","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2025.104407_b0955","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1128\/MCB.00248-15","article-title":"Analysis of the role of the C-terminal tail in the regulation of the epidermal growth factor receptor","volume":"35","author":"Kovacs","year":"2015","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.drudis.2025.104407_b0960","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3389\/fonc.2019.00800","article-title":"Rethink of EGFR in cancer with its kinase independent function on board","volume":"9","author":"Thomas","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2025.104407_b0965","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.tips.2013.04.007","article-title":"Targeting protein\u2013protein interactions as an anticancer strategy","volume":"34","author":"Ivanov","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2025.104407_b0970","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nature06526","article-title":"Reaching for high-hanging fruit in drug discovery at protein\u2013protein interfaces","volume":"450","author":"Wells","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104407_b0975","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.pharmtox.48.113006.094723","article-title":"Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy","volume":"49","author":"Shangary","year":"2009","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.drudis.2025.104407_b0980","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00315-3","article-title":"Recent advances in the development of protein\u2013protein interactions modulators: mechanisms and clinical trials","volume":"5","author":"Lu","year":"2020","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.drudis.2025.104407_b0985","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.drudis.2025.104407_b0990","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/17460441.2023.2198699","article-title":"Where to next in the evolution of in silico design of modulators targeting protein\u2013protein interactions?","volume":"18","author":"Wang","year":"2023","journal-title":"Expert Opin Drug Discov"}],"updated-by":[{"DOI":"10.1016\/j.drudis.2025.104426","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000}}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625001205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625001205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T03:16:40Z","timestamp":1764818200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625001205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":198,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1359644625001205"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104407","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104407"}}